# A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

> **NCT00435084** · PHASE1,PHASE2 · COMPLETED · sponsor: **Valerio Therapeutics** · enrollment: 10 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** APO866

## Key facts

- **NCT ID:** NCT00435084
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-02
- **Final completion:** 2009-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00435084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00435084, "A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00435084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*